Operating Income (Loss) in USD of Eloxx Pharmaceuticals, Inc. from 2010 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Eloxx Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and change rate from 2010 to Q3 2023.
  • Eloxx Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending 30 Sep 2023 was -$3.64M, a 49.1% increase year-over-year.
  • Eloxx Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending 30 Sep 2023 was -$19.3M, a 51.8% increase year-over-year.
  • Eloxx Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$34.4M, a 47.9% increase from 2021.
  • Eloxx Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$66M, a 97.3% decline from 2020.
  • Eloxx Pharmaceuticals, Inc. annual Operating Income (Loss) for 2020 was -$33.5M, a 33.8% increase from 2019.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

Eloxx Pharmaceuticals, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2023 -$19.3M -$3.64M +$3.51M +49.1% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2023
Q2 2023 -$22.8M -$4.14M +$6.16M +59.8% 01 Apr 2023 30 Jun 2023 10-Q 11 Aug 2023
Q1 2023 -$28.9M -$5.48M +$5.47M +49.9% 01 Jan 2023 31 Mar 2023 10-Q 12 May 2023
Q4 2022 -$34.4M -$6.03M +$5.6M +48.2% 01 Oct 2022 31 Dec 2022 10-K 31 Mar 2023
Q3 2022 -$40M -$7.14M +$3.1M +30.3% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023
Q2 2022 -$43.1M -$10.3M +$25.4M +71.2% 01 Apr 2022 30 Jun 2022 10-Q 11 Aug 2023
Q1 2022 -$68.6M -$11M -$2.54M -30.2% 01 Jan 2022 31 Mar 2022 10-Q 12 May 2023
Q4 2021 -$66M -$11.6M -$5.82M -100% 01 Oct 2021 31 Dec 2021 10-K 31 Mar 2023
Q3 2021 -$60.2M -$10.2M -$3.95M -62.7% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022
Q2 2021 -$56.2M -$35.7M -$28.1M -371% 01 Apr 2021 30 Jun 2021 10-Q 12 Aug 2022
Q1 2021 -$28.1M -$8.41M +$5.35M +38.9% 01 Jan 2021 31 Mar 2021 10-Q 06 May 2022
Q4 2020 -$33.5M -$5.81M +$5.68M +49.5% 01 Oct 2020 31 Dec 2020 10-K 30 Mar 2022
Q3 2020 -$39.1M -$6.3M +$6.48M +50.7% 01 Jul 2020 30 Sep 2020 10-Q 08 Nov 2021
Q2 2020 -$45.6M -$7.59M +$6.73M +47% 01 Apr 2020 30 Jun 2020 10-Q 16 Aug 2021
Q1 2020 -$52.3M -$13.8M -$1.79M -14.9% 01 Jan 2020 31 Mar 2020 10-Q 07 May 2021
Q4 2019 -$50.6M -$11.5M +$2.63M +18.6% 01 Oct 2019 31 Dec 2019 10-K 30 Mar 2022
Q3 2019 -$53.2M -$12.8M -$1.42M -12.5% 01 Jul 2019 30 Sep 2019 10-Q 06 Nov 2020
Q2 2019 -$51.8M -$14.3M -$768K -5.67% 01 Apr 2019 30 Jun 2019 10-Q 07 Aug 2020
Q1 2019 -$51M -$12M -$3.43M -40.1% 01 Jan 2019 31 Mar 2019 10-Q 08 May 2020
Q4 2018 -$47.6M -$14.1M -$3.54M -33.4% 01 Oct 2018 31 Dec 2018 10-K 12 Mar 2021
Q3 2018 -$44M -$11.4M -$7.36M -184% 01 Jul 2018 30 Sep 2018 10-Q 06 Nov 2019
Q2 2018 -$36.7M -$13.5M -$10.4M -326% 01 Apr 2018 30 Jun 2018 10-Q 07 Aug 2019
Q1 2018 -$26.3M -$8.55M -$5.92M -225% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019
Q4 2017 -$20.4M -$10.6M -$9.07M -602% 01 Oct 2017 31 Dec 2017 10-K 06 Mar 2020
Q3 2017 -$11.3M -$4M -$1.79M -81% 01 Jul 2017 30 Sep 2017 10-Q 08 Nov 2018
Q2 2017 -$9.53M -$3.18M 01 Apr 2017 30 Jun 2017 10-Q 10 Aug 2018
Q1 2017 -$2.63M +$2.26M +46.2% 01 Jan 2017 31 Mar 2017 10-Q 10 May 2018
Q4 2016 -$1.51M +$2.25M +59.9% 01 Oct 2016 31 Dec 2016 10-Q 10 Feb 2017
Q3 2016 -$2.21M -$1.06M -92% 01 Jul 2016 30 Sep 2016 10-Q 14 Nov 2016
Q1 2016 -$4.89M -$3.66M -299% 01 Jan 2016 31 Mar 2016 10-Q 22 May 2017
Q4 2015 -$3.76M +$6.99M +65% 01 Oct 2015 31 Dec 2015 10-Q 10 Feb 2017
Q3 2015 -$1.15M +$4.03M +77.8% 01 Jul 2015 30 Sep 2015 10-Q 14 Nov 2016
Q1 2015 -$20.8M -$1.22M +$904K +42.5% 01 Jan 2015 31 Mar 2015 10-Q 12 May 2016
Q4 2014 -$21.7M -$10.7M -$9.16M -576% 01 Oct 2014 31 Dec 2014 10-Q 16 Feb 2016
Q3 2014 -$12.6M -$5.19M -$3.43M -196% 01 Jul 2014 30 Sep 2014 10-Q 16 Nov 2015
Q2 2014 -$9.15M -$3.68M -$2.62M -247% 01 Apr 2014 30 Jun 2014 10-K 13 Oct 2016
Q1 2014 -$6.53M -$2.13M -$1.08M -104% 01 Jan 2014 31 Mar 2014 10-Q 14 May 2015
Q4 2013 -$5.45M -$1.59M -$289K -22.2% 01 Oct 2013 31 Dec 2013 10-Q 17 Feb 2015
Q3 2013 -$5.16M -$1.75M -$507K -40.7% 01 Jul 2013 30 Sep 2013 10-Q 14 Nov 2014
Q2 2013 -$4.65M -$1.06M +$506K +32.3% 01 Apr 2013 30 Jun 2013 10-K 09 Oct 2015
Q1 2013 -$5.16M -$1.04M +$64.5K +5.81% 01 Jan 2013 31 Mar 2013 10-Q 09 May 2014
Q4 2012 -$5.22M -$1.3M +$156K +10.7% 01 Oct 2012 31 Dec 2012 10-Q 14 Feb 2014
Q3 2012 -$5.38M -$1.25M +$34K +2.66% 01 Jul 2012 30 Sep 2012 10-Q 14 Nov 2013
Q2 2012 -$5.41M -$1.57M +$1.27M +44.9% 01 Apr 2012 30 Jun 2012 10-K 29 Sep 2014
Q1 2012 -$6.69M -$1.11M +$259K +18.9% 01 Jan 2012 31 Mar 2012 10-Q 15 May 2013
Q4 2011 -$6.94M -$1.46M +$48.9K +3.25% 01 Oct 2011 31 Dec 2011 10-Q 14 Feb 2013
Q3 2011 -$6.99M -$1.28M +$925K +42% 01 Jul 2011 30 Sep 2011 10-Q 14 Nov 2012
Q2 2011 -$7.92M -$2.84M 01 Apr 2011 30 Jun 2011 10-K 11 Sep 2013
Q1 2011 -$1.37M 01 Jan 2011 31 Mar 2011 10-Q 14 May 2012
Q4 2010 -$1.51M 01 Oct 2010 31 Dec 2010 10-Q 14 Feb 2012
Q3 2010 -$2.21M 01 Jul 2010 30 Sep 2010 10-Q 14 Nov 2011

Eloxx Pharmaceuticals, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2022 -$34.4M +$31.6M +47.9% 01 Jan 2022 31 Dec 2022 10-K 31 Mar 2023
2021 -$66M -$32.6M -97.3% 01 Jan 2021 31 Dec 2021 10-K 31 Mar 2023
2020 -$33.5M +$17.1M +33.8% 01 Jan 2020 31 Dec 2020 10-K 30 Mar 2022
2019 -$50.6M -$2.99M -6.29% 01 Jan 2019 31 Dec 2019 10-K 30 Mar 2022
2018 -$47.6M -$27.2M -133% 01 Jan 2018 31 Dec 2018 10-K 12 Mar 2021
2017 -$20.4M -$10.6M -107% 01 Jan 2017 31 Dec 2017 10-K 06 Mar 2020
2016 -$9.84M -$3.56M -56.6% 01 Jan 2016 31 Dec 2016 10-K 14 Mar 2019
2015 -$6.28M +$2.86M +31.3% 01 Jan 2015 31 Dec 2015 10-K 16 Mar 2018
2014 -$9.15M -$4.5M -96.7% 01 Jul 2013 30 Jun 2014 10-K 13 Oct 2016
2013 -$4.65M +$761K +14.1% 01 Jul 2012 30 Jun 2013 10-K 09 Oct 2015
2012 -$5.41M +$2.51M +31.7% 01 Jul 2011 30 Jun 2012 10-K 29 Sep 2014
2011 -$7.92M -$3.07M -63.4% 01 Jul 2010 30 Jun 2011 10-K 11 Sep 2013
2010 -$4.85M 01 Jul 2009 30 Jun 2010 10-K/A 26 Oct 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.